Top Markets
#1 MowCat MowCat +48.88%
#2 Bermuda Shorts Bermuda Shorts +25.27%
#3 Velvet Velvet +25.14%
#4 Derive Derive +21.09%
#5 Audiera Audiera +20.34%
#6 Biconomy Biconomy +18.91%
#7 aPriori aPriori +18.15%
#8 Quack AI Quack AI +17.54%
#9 Geodnet Geodnet +12.27%
#10 Perle Perle +10.44%
Coin of the day
MowCat MowCat
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc.

MYMD
Rang in Aktien #35400
MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical... MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical development stage, focused on devising diverse therapeutic strategies that target the underlying origins of various illnesses. One of its key initiatives is the development of MYMD-1, a drug platform centered on a small molecule presently undergoing clinical trials. This molecule works by regulating the immune system to suppress TNF-alpha, a major contributor to chronic inflammation, along with other pro-inflammatory cell-signaling proteins. MYMD-1 is being explored for its potential to delay aging, extend lifespan, manage autoimmune conditions, and treat depression linked to COVID-19. Furthermore, the company is advancing Supera-CBD, a synthetic version of cannabidiol, which aims to address chronic pain, addiction, and epilepsy. MyMD Pharmaceuticals was established in 2014 and its corporate headquarters are situated in Baltimore, Maryland.
Aktienkurs
$1.85
Zuletzt synchronisiert: 2024-08-19
Marktkapitalisierung
$3.96M
Veränderung (1 Tag)
2.78%
Veränderung (1 Jahr)
0.00%
Land
US
Handel MyMD Pharmaceuticals, Inc. (MYMD)

Kategorie

Healthcare
P/B-Verhältnis für MyMD Pharmaceuticals, Inc. (MYMD)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von MyMD Pharmaceuticals, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für MyMD Pharmaceuticals, Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE